Augmedix, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Augmedix, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Augmedix, Inc. has recorded 19 reports. The latest transaction was filed on 27 May 2022 (Acquisition). Among the most active insiders: Ginocchio Paul. The full history is openly available.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 May 2022
All Executives19 Thresholds0 Prospectus0 Other0
Declarations 19 total
▲ Director · Executives · 27 May 2022
30,000 shares @ US$1.99 100.0% of flow Common Stock SEC:0001213900-22-030199:0
Canonical exit: 25 Aug 2022 (T+90) ▲ CHIEF FINANCIAL OFFICER · Executives · 26 May 2022
16,000 shares @ US$1.99 5.6% of flow Common Stock SEC:0001213900-22-030198:0
Canonical exit: 24 Aug 2022 (T+90) ▲ Director · Executives · 26 May 2022
7,305 shares @ US$1.98 54.3% of flow Common Stock SEC:0001213900-22-030197:0
Canonical exit: 24 Aug 2022 (T+90) ◆ Chief Strategy Officer · Executives · 3 Dec 2021
3,000 shares @ US$3.40 50.0% of flow Common Stock SEC:0001209191-21-067763:0
▲ Director · Executives · 26 Nov 2021
918 shares @ US$3.53 11.6% of flow Common Stock SEC:0001213900-21-062382:0
Canonical exit: 24 Feb 2022 (T+90) ▲ PRESIDENT, CEO, AND SECRETARY · Executives · 24 Nov 2021
15,551 shares @ US$3.20 12.8% of flow Common Stock SEC:0001213900-21-062044:0
Canonical exit: 22 Feb 2022 (T+90) ▲ CHIEF FINANCIAL OFFICER · Executives · 23 Nov 2021
14,000 shares @ US$2.96 7.0% of flow Common Stock SEC:0001213900-21-061681:0
Canonical exit: 21 Feb 2022 (T+90) ▲ Director · Executives · 26 Oct 2021
900 shares @ US$3.59 11.2% of flow Common Stock SEC:0001213900-21-060408:0
Canonical exit: 24 Jan 2022 (T+90) ▲ CHIEF OPERATING OFFICER · Executives · 28 Oct 2021
12,500 shares @ US$4.00 50.0% of flow Common Stock SEC:0001213900-21-055926:0
Canonical exit: 26 Jan 2022 (T+90) ▲ Director · Executives · 28 Oct 2021
87,500 shares @ US$4.00 50.0% of flow Common Stock SEC:0001213900-21-055921:0
Canonical exit: 26 Jan 2022 (T+90) ▲ Director · Executives · 28 Oct 2021
1,625,000 shares @ US$4.00 50.0% of flow Common Stock SEC:0001104659-21-132515:0
Canonical exit: 26 Jan 2022 (T+90) ▲ Director · Executives · 28 Oct 2021
437,500 shares @ US$4.00 50.0% of flow Common Stock SEC:0001213900-21-055919:0
Canonical exit: 26 Jan 2022 (T+90) ▲ Director · Executives · 28 Oct 2021
87,500 shares @ US$4.00 50.0% of flow Common Stock SEC:0001213900-21-055912:0
Canonical exit: 26 Jan 2022 (T+90) ▲ PRESIDENT, CEO, AND SECRETARY · Executives · 28 Oct 2021
37,500 shares @ US$4.00 37.2% of flow Common Stock SEC:0001213900-21-055925:0
Canonical exit: 26 Jan 2022 (T+90) ▲ Director · Executives · 28 Oct 2021
437,500 shares @ US$4.00 50.0% of flow Common Stock SEC:0001213900-21-055917:0
Canonical exit: 26 Jan 2022 (T+90) ▲ CHIEF FINANCIAL OFFICER · Executives · 28 Oct 2021
34,000 shares @ US$4.00 22.0% of flow Common Stock SEC:0001213900-21-055923:0
Canonical exit: 26 Jan 2022 (T+90) ▲ CHIEF FINANCIAL OFFICER · Executives · 7 Jun 2021
10,000 shares @ US$5.00 13.7% of flow Common Stock SEC:0001213900-21-031673:0
Canonical exit: 5 Sept 2021 (T+90) ▲ CHIEF FINANCIAL OFFICER · Executives · 25 May 2021
9,356 shares @ US$4.56 11.6% of flow Common Stock SEC:0000899243-21-020924:0
Canonical exit: 23 Aug 2021 (T+90) ▲ Chief Financial Officer · Executives · 19 May 2021
12,600 shares @ US$3.96 13.7% of flow Common Stock SEC:0000899243-21-020403:0
Canonical exit: 17 Aug 2021 (T+90) 关于 Augmedix, Inc. Augmedix, Inc. 曾是一家专注于环境AI医疗文档的美国医疗技术公司。在被收购之前,该公司股票在纳斯达克交易,股票代码为AUGX,公司总部位于美国加利福尼亚州旧金山。Augmedix 成立于 2013 年,并于 2014 年推出了商业实时远程文档服务。从投资者的角度来看,该公司解决了医疗保健领域一个明显的结构性问题:临床医生花费过多时间在行政文档上,而非患者护理,尤其是在受电子健康记录工作流程和劳动力短缺困扰的环境中。
随着时间的推移,Augmedix 从远程抄写员模式发展成为一个更广泛的文档平台,该平台围绕不同级别的AI自动化和人工支持构建。2024 年,该公司表示其业务将专注于两款核心产品:Augmedix Go 和 Augmedix Live。Augmedix Go 是自动化程度更高、由AI驱动的产品,旨在快速起草临床笔记,而 Augmedix Live 则通过医疗文档专家提供实时文档支持。该公司还推出了混合配置,例如 Augmedix Assist,允许客户在自动化和人工审查之间选择适当的平衡。这种灵活性很重要,因为临床工作流程因专业、护理环境和医生偏好而异。
Augmedix 在环境AI和临床文档市场中与听写软件供应商、非实时笔记生成工具以及其他实时医疗抄写员提供商竞争。其竞争优势在于结合了软件、AI、工作流程集成和人工操作支持。该产品套件旨在与客户的 EHR 环境集成,并服务于医院、卫生系统、医生团体和独立诊所。尽管该公司的商业重点主要在美国,但其运营足迹历来包括国际支持中心,这反映了服务模式的劳动密集型性质。
近期的一项重大发展是 Commure 的收购。2024 年 7 月,Augmedix 宣布将与 Commure 合并,并于 2024 年 10 月 2 日,Commure 完成了收购。交易完成后,Augmedix 成为 Commure 的全资子公司,其股票停止在纳斯达克交易。对于投资者而言,这是一个关键的背景点:Augmedix 不再是独立上市的公开股权,因此应根据公司从公开市场上市到私人所有权的过渡来解释历史 SEC Form 4 内部人交易。尽管如此,该公司仍然是医疗保健文档环境AI商业化和该行业整合的一个相关案例研究。